Multiple Sclerosis - FOI Response Register

1. How many people are there with a diagnosis of MS in your Health Board area?

92

2. How many people with MS in your Health Board area (including the source for this number)
are diagnosed as the following:

Source primary care data extracted via EMIS

a. Relapsing-Remitting MS

Read Code: F207

15

b. Primary Progressive MS

Read Code: F206

2

c. Secondary Progressive MS

Read Code: F208

4

d. Benign MS

Read Code: F204

0

e. Unconfirmed Type

Read Code: F20z

4

PART 2

3. Are the following licenced drugs for multiple sclerosis (MS) approved for use on your local
drugs formulary; and

All are approved for use.

4. Are the following licenced drugs for multiple sclerosis (MS) subject to any specific financial or
clinical prescribing restrictions within your health board?

All except Sativex are only approved for prescribing by Specialists based in a hospital
setting. Sativex is available under specialist supervision, being initiated in hospital prior to
hand over to other clinicians.

Avonex (interferon beta-1a) 0
Rebif (interferon beta-1a) 0
Plegridy (peginterferon beta-1a) 0
Betaferon (interferon beta 1b) 0
Extavia (interferon beta 1b) 1
Aubagio (teriflunomide) 1
Copaxone (glatiramer acetate) 1
Gilenya (fingolimod) 1
Lemtrada (alemtuzumab) 0
Ofatumumab (Kesimpta) 2
Ozanimod (Zeposia) 0
Plegidry (peginterferon beta 1a) Duplicate
Ponesimod (Ponvory) 0
Siponimod (Mayzent) 0
Tecfidera (dimethyl fumarate) 16
Tysabri (natalizumab) 0
Mavenclad (Cladribine) 0
Ocrevus (ocrelizumab) 0
Sativex (nabiximols) 4
Fampyra (fampridine) 7

PART 3

5. Please provide a breakdown of the number of people with MS currently being prescribed
each of the licenced drugs shown in PART 2.

See above